Your browser doesn't support javascript.
loading
Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis.
You, Xin; Jiang, Weiye; Lu, Wenhua; Zhang, Hui; Yu, Tiantian; Tian, Jingyu; Wen, Shijun; Garcia-Manero, Guillermo; Huang, Peng; Hu, Yumin.
Afiliação
  • You X; Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.
  • Jiang W; The First Department of Chemotherapy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, Fujian, P. R. China.
  • Lu W; Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.
  • Zhang H; Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.
  • Yu T; Metabolic Innovation Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China.
  • Tian J; Metabolic Innovation Center, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China.
  • Wen S; Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.
  • Garcia-Manero G; Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China.
  • Huang P; Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Hu Y; Department of Experimental Therapeutics, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, 651 Dong Feng East Road, Guangzhou, 510060, Guangdong, P. R. China. huangpeng@sysucc.org.cn.
Cancer Commun (Lond) ; 39(1): 17, 2019 04 04.
Article em En | MEDLINE | ID: mdl-30947742
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Tirosina Quinase 3 Semelhante a fms / Sorafenibe / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Tirosina Quinase 3 Semelhante a fms / Sorafenibe / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article